Potent and selective Bruton's tyrosine kinase inhibitors: Discovery of GDC-0834

被引：56

作者：

Young, Wendy B. ^{[1
]}

Barbosa, James ^{[2
]}

Blomgren, Peter ^{[2
]}

Bremer, Meire C. ^{[1
]}

Crawford, James J. ^{[1
]}

Dambach, Donna ^{[1
]}

Gallion, Steve

Hymowitz, Sarah G. ^{[1
]}

Kropf, Jeffrey E. ^{[2
]}

Lee, Seung H. ^{[2
]}

Liu, Lichuan ^{[1
]}

Lubach, Joseph W. ^{[1
]}

Macaluso, Jen ^{[2
]}

Maciejewski, Pat ^{[2
]}

Maurer, Brigitte ^{[1
]}

Mitchell, Scott A. ^{[2
]}

Ortwine, Daniel F. ^{[1
]}

Di Paolo, Julie ^{[2
]}

Reif, Karin ^{[1
]}

Scheerens, Heleen ^{[1
]}

Schmitt, Aaron ^{[2
]}

Sowell, C. Gregory ^{[1
]}

Wang, Xiaojing ^{[1
]}

Wong, Harvey ^{[1
]}

Xiong, Jin-Ming ^{[2
]}

Xu, Jianjun ^{[2
]}

Zhao, Zhongdong ^{[2
]}

Currie, Kevin S. ^{[2
]}

机构：

[1] Genentech Inc, San Francisco, CA 94080 USA

[2] Gilead Sci Inc, Branford, CT 06405 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2015年 / 25卷 / 06期

关键词：

Kinase inhibitor; Bruton's tyrosine kinase; Btk; Rheumatoid arthritis; GDC-0834; Amide hydrolysis; Single dose IND; COLLAGEN-INDUCED ARTHRITIS; B-CELL; INFLAMMATORY DISEASES; IBRUTINIB;

D O I：

10.1016/j.bmcl.2015.01.032

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

SAR studies focused on improving the pharmacokinetic (PK) properties of the previously reported potent and selective Btk inhibitor CGI-1746 (1) resulted in the clinical candidate GDC-0834 (2), which retained the potency and selectivity of CGI-1746, but with much improved PK in preclinical animal models. Structure based design efforts drove this work as modifications to 1 were investigated at both the solvent exposed region as well as 'H3 binding pocket'. However, in vitro metabolic evaluation of 2 revealed a non CYP-mediated metabolic process that was more prevalent in human than preclinical species (mouse, rat, dog, cyno), leading to a high-level of uncertainly in predicting human pharmacokinetics. Due to its promising potency, selectivity, and preclinical efficacy, a single dose IND was filed and 2 was taken in to a single dose phase I trial in healthy volunteers to quickly evaluate the human pharmacokinetics. In human, 2 was found to be highly labile at the exo-cyclic amide bond that links the tetrahydrobenzothiophene moiety to the central aniline ring, resulting in insufficient parent drug exposure. This information informed the back-up program and discovery of improved inhibitors. (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：1333 / 1337

页数：5

共 50 条

[11] Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase [J].

Kawahata, Wataru ;

Asami, Tokiko ;

Kiyoi, Takao ;

Irie, Takayuki ;

Kashimoto, Shigeki ;

Furuichi, Hatsuo ;

Sawa, Masaaki .

JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (19) :14129-14141

[12] Discovery of Pteridine-7(8H)-one Derivatives as Potent and Selective Inhibitors of Bruton's Tyrosine Kinase (BTK) [J].

Dou, Dou ;

Diao, Yanyan ;

Sha, Wenjie ;

Su, Rongrong ;

Tong, Linjiang ;

Li, Wenjie ;

Leng, Limin ;

Xie, Lijuan ;

Yu, Zhixiao ;

Song, Haoming ;

Shen, Zihao ;

Zhu, Lili ;

Zhao, Zhenjiang ;

Xie, Hua ;

Chen, Zhuo ;

Li, Honglin ;

Xu, Yufang .

JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (03) :2694-2709

[13] Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases [J].

Caldwell, Richard D. ;

Qiu, Hui ;

Askew, Ben C. ;

Bender, Andrew T. ;

Brugger, Nadia ;

Camps, Montserrat ;

Dhanabal, Mohanraj ;

Dutt, Vikram ;

Eichhorn, Thomas ;

Gardberg, Anna S. ;

Goutopoulos, Andreas ;

Grenningloh, Roland ;

Head, Jared ;

Healey, Brian ;

Hodous, Brian L. ;

Huck, Bayard R. ;

Johnson, Theresa L. ;

Jones, Christopher ;

Jones, Reinaldo C. ;

Mochalkin, Igor ;

Morandi, Federica ;

Ngan Nguyen ;

Meyring, Michael ;

Potnick, Justin R. ;

Santos, Dusica Cvetinovic ;

Schmidt, Ralf ;

Sherer, Brian ;

Shutes, Adam ;

Urbahns, Klaus ;

Follis, Ariele Viacava ;

Wegener, Ansgar A. ;

Zimmerli, Simone C. ;

Liu-Bujalski, Lesley .

JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (17) :7643-7655

[14] Discovery of a Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase with Oral Anti-Inflammatory Activity [J].

Tichenor, Mark S. ;

Wiener, John J. M. ;

Rao, Navin L. ;

Deckhut, Charlotte Pooley ;

Barbay, J. Kent ;

Kreutter, Kevin D. ;

Bacani, Genesis M. ;

Wei, Jianmei ;

Chang, Leon ;

Murrey, Heather E. ;

Wang, Weixue ;

Ahn, Kay ;

Huber, Michael ;

Rex, Elizabeth ;

Coe, Kevin J. ;

Wu, JieJun ;

Seierstad, Mark ;

Bembenek, Scott D. ;

Leonard, Kristi A. ;

Lebsack, Alec D. ;

Venable, Jennifer D. ;

Edwards, James P. .

ACS MEDICINAL CHEMISTRY LETTERS, 2021, 12 (05) :782-790

[15] Discovery of Imidazo[1,2-b]pyridazine Derivatives as Potent and Highly Selective Irreversible Bruton's Tyrosine Kinase (BTK) Inhibitors [J].

Zhang, Dandan ;

Zhao, Jie ;

Xu, Guiqing ;

Wang, Yue ;

Li, Yang ;

Ren, Hanxiao ;

Geng, Jiajun ;

Du, Yu ;

Zhang, Chenchen ;

Yang, Shouning ;

Liu, Dongfang ;

Gao, Jiajing ;

Xiong, Yi ;

Zhang, Haoyi ;

Li, Wei ;

Wang, Wei ;

Wang, Di ;

Li, Biao ;

He, Xing ;

Ma, Chunhua ;

Jiang, Yuqin ;

Ding, Qingjie .

JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (11) :10897-10929

[16] New Insights on Bruton's Tyrosine Kinase Inhibitors [J].

Smith, C. I. Edvard ;

Brown, Jennifer R. ;

Zain, Rula .

FRONTIERS IN IMMUNOLOGY, 2021, 12

[17] Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis [J].

Norman, Peter .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (08) :891-899

[18] The Use of Bruton's Tyrosine Kinase Inhibitors to Treat Allergic Disorders [J].

Dispenza, Melanie C. .

CURRENT TREATMENT OPTIONS IN ALLERGY, 2021, 8 (03) :261-273

[19] Discovery of Tricyclic Pyranochromenone as Novel Bruton's Tyrosine Kinase Inhibitors with In Vivo Antirheumatic Activity [J].

Cho, Hyewon ;

Lee, Eun ;

Kwon, Hye Ah ;

Seul, Lee ;

Jeon, Hui-Jeon ;

Yu, Ji Hoon ;

Ryu, Jae-Ha ;

Jeon, Raok .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (21) :1-15

[20] Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis [J].

Yao, Xia ;

Sun, Xiuyun ;

Jin, Shuyu ;

Yang, Ling ;

Xu, Hongjiang ;

Rao, Yu .

JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (14) :6561-6574

← 1 2 3 4 5 →